Longeveron (NASDAQ: LGVN)
Longeveron Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Longeveron Company Info
Longeveron, Inc. is a clinical stage biotechnology company. It engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers on October 9, 2014 and is headquartered in Miami, FL.
News & Analysis
Here's Why Longeveron Stock Jumped Higher on Wednesday
Investors are reacting positively to the beginning of an Alzheimer's disease trial with Longeveron's lead candidate, Lomadel-B.
Is It Too Late to Buy Longeveron Stock?
No, but make sure you understand what you're getting into.
Why Longeveron Stock Skyrockted 661.2% in November
The biotech stock is now up 171.5% year to date.
Is Longeveron a Good Biotech Stock to Buy?
Stem cell therapies are back in vogue, at least for this Miami-based biotechnology company.
Here's Why Longeveron Is Surging Today
An orphan drug designation for the treatment of a rare heart condition is pushing the biotech stock higher.
Why Longeveron Stock Is Skyrocketing Today
A short squeeze appears to be underway.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.